15 Jul Accellix
Stanley Bonn, Business Development Manager
Oct. 6 | 11:30am | FLW Ballroom G
San Jose, CA
(Private)
Founded in 2007, Accellix has been redefining cell phenotyping through rapid, automated flow cytometry solutions that simplify complex workflows and deliver critical quality insights directly to the point of need. Its automated ACCELLIX™ Platform delivers rapid flow cytometry–based analysis for cell therapy development, manufacturing, and quality control, enabling measurement of critical quality attributes throughout the manufacturing process and product release. The platform also supports characterization of blood-derived apheresis products used in research, donor screening, and the development of advanced therapies. In January 2026, bioMérieux, a world leader in the field of in vitro diagnostics since 1963, acquired Accellix, strengthening its Pharmaceutical Quality Control portfolio with rapid, automated flow cytometry solutions for cell and gene therapy. This strategic investment expands bioMérieux’s support for the growing advanced therapies market and reinforces its commitment to improving patient outcomes worldwide.